CEL SCI CORP

CEL-SCI Corporation announced its Annual Meeting of Shareholders will take place on August 14, 2026, to address several key proposals. Shareholders will vote on the election of directors, the adoption of the 2026 Non-Qualified Stock Option Plan and the 2026 Stock Bonus Plan. Additionally, there will be non-binding advisory votes on executive officer compensation and the frequency of such votes, along with the ratification of BDO USA, P.C. as the independent auditor. The record date for shareholders entitled to vote is June 18, 2026.

CEL-SCI Corporation announced the closing of a best-efforts offering, selling 2,500,000 shares of its common stock at $1.00 per share. This transaction generated gross proceeds of $2.5 million, before deducting placement agent fees and offering expenses. The company intends to utilize the net proceeds to fund the continued development of Multikine, for general corporate purposes, and working capital. ThinkEquity LLC acted as the sole placement agent for the offering.

CEL SCI Corporation reported a net loss of $(5,465,751) for the three months ended March 31, 2026, and $(10,935,197) for the six months, showing a reduction in losses compared to the prior year. However, the company's cash and cash equivalents significantly decreased to $1.89 million from $10.95 million over the past six months, leading to substantial doubt about its ability to continue as a going concern. The company plans to raise additional capital through partnerships, debt, and/or equity financings to fund its operations and bring its lead investigational therapy, Multikine, to market.

CEL-SCI Corporation announced a strategic partnership, distribution, and revenue sharing agreement with Amarox for its cancer immunotherapy, Multikine, in Saudi Arabia. The agreement includes a 50%/50% net revenue sharing model for sales of Multikine, intended for head and neck cancer treatment, upon SFDA approval. Amarox will manage local regulatory processes, including seeking Breakthrough Medicine Designation, and will be the exclusive distributor in Saudi Arabia, with an option to expand to other GCC countries. This collaboration aims to accelerate Multikine's commercialization in a region where the immunotherapy market is projected to reach $2.7 billion by 2033.

CEL-SCI Corporation announced the closing of a public offering on May 13, 2026, selling 6,000,000 shares of its common stock at $1.20 per share. This offering generated gross proceeds of $7.2 million before deducting fees and expenses. The company plans to use the net proceeds to fund the continued development of Multikine, for general corporate purposes, and working capital. ThinkEquity LLC served as the sole placement agent for the offering.

CEL-SCI Corporation filed an S-1/A to offer up to 4,885,993 shares of common stock and an equal number of pre-funded warrants, aiming to raise approximately $13.7 million in net proceeds. The offering, on a best efforts basis with ThinkEquity LLC, has no minimum requirement and is expected to fund the continued development of its lead immunotherapy, Multikine, and for general corporate purposes. The company also highlighted positive Phase III clinical trial results for Multikine in head and neck cancer, showing a 73% 5-year survival rate in the target population, and announced FDA clearance to proceed with a 212-patient confirmatory registration study.